Radiosensitivity of human colon cancer cell enhanced by immunoliposomal docetaxel

World Journal of Gastroenterology

Volumn 11, Issue 26, 2005, Pages 4003-4007

  Wang, Qing Wei ^a   Lü, Hui Lan ^a   Song, Chang Cheng ^b   Liu, Hong ^a   Xu, Cong Gao ^a  

^a SHANDONG UNIVERSITY   (China)

^b SAIC FREDERICK INC   (United States)

Author keywords

Docetaxel; Human colon cancer cell; Immunoliposomes; Radiosensitivity

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CYANURIC ACID; DOCETAXEL; IMMUNOLIPOSOME; MACROGOL; SURVIVIN;

ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CARCINOMA CELL; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL STRUCTURE; COLON CANCER; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADIATION DOSE; RADIATION EXPOSURE; RADIOSENSITIVITY; RADIOSENSITIZATION;

EID: 24144444516     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i26.4003     Document Type: Article

References (31)

1. Shunyakov L, Ryan CK, Sahasrabudhe DM, Khorana AA. The influence of host response on colorectal cancer prognosis. Clin Colorectal Cancer 2004; 4: 38-45
2. Sarid D, Wigler N, Gutkin Z, Merimsky O, Leider-Trejo L, Ron IG. Cutaneous and subcutaneous metastases of rectal cancer. Int J Clin Oncol 2004; 9: 202-205
3. Munro AJ, Bentley AH. Deprivation, comorbidity and survival in a cohort of patients with colorectal cancer. Eur J Cancer Care 2004; 13: 254-262
4. Hahnloser D, Haddock MG, Nelson H. Intraoperative radiotherapy in the multimodality approach to colorectal cancer. Surg Oncol Clin N Am 2003; 12: 993-1013
5. Hocht S, Hammad R, Thiel HJ, Wiegel T, Siegmann A, Willner J, Wust P, Herrmann T, Eble M, Flentje M, Carstens D, Bottke D, Neumann P, Hinkelbein W. Recurrent rectal cancer within the pelvis. A multicenter analysis of 123 patients and recommendations for adjuvant radiotherapy. Strahlenther Onkol 2004; 180: 15-20
6. Souglakos J, Androulakis N, Mavroudis D, Kourousis C, Kakolyris S, Vardakis N, Kalbakis K, Pallis A, Ardavanis A, Varveris C, Georgoulias V. Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer. Int J Radiat Oncol Biol Phys 2003; 56: 1284-1287
7. Horgan AF, Finlay IG. Preoperative staging of rectal cancer allows selection of patients for preoperative radiotherapy. Br J Surg 2000; 87: 575-579
8. Onishi H, Kuriyama K, Yamaguchi M, Komiyama T, Tanaka S, Araki T, Nishikawa K, Ishihara H. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. Lung Cancer 2003; 40: 79-84
9. Mason KA, Hunter NR, Milas M, Abbruzzese JL, Milas L. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 1997; 3: 2431-2438
10. Fernando NH, Hurwitz HI. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist 2004; 9(Suppl 1): 11-18
11. Veronese ML, O'Dwyer PJ. Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer 2004; 40: 1292-1301
12. Vavrova J, Rezacova M, Vokurkova D, Psutka J. Cell cycle alteration, apoptosis and response of leukemic cell lines to gamma radiation with high- and low-dose rate. Physiol Res 2004; 53: 335-342
13. Belka C, Jendrossek V, Pruschy M, Vink S, Verheij M, Budach W. Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. Int J Radiat Oncol Biol Phys 2004; 58: 542-554
14. Bendas G, Krause A, Bakowsky U, Vogel J, Rothe U. Targetability of novel immunoliposomes prepared by a new antibody conjugation technique. Int J Pharm 1999; 181: 79-93
15. Rossi L, Corvo R. Retinoic acid modulates the radiosensitivity of head-and-neck squamous carcinoma cells grown in collagen gel. Int J Radiat Oncol Biol Phys 2002; 53: 1319-1327
16. Raju U, Nakata E, Yang P, Newman RA, Ang KK, Milas L. In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations. Int J Radiat Oncol Biol Phys 2002; 54: 886-894
17. Ray-Coquard I. Docetaxel and ovarian cancer. Bull Cancer 2004; 91: 159-165
18. Yardley DA. Gemcitabine and docetaxel in metastatic and neoadjuvant treatment of breast cancer. Semin Oncol 2004; 31 (2 Suppl 5): 37-44
19. Mani S, Macapinlac M Jr, Goel S, Verdier-Pinard D, Fojo T, Rothenberg M, Colevas D. The clinical development of new mitotic inhibitors that stabilize the microtubule. Anticancer Drugs 2004; 15: 553-558
20. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Vile RG, Uster PS, Peters AM, Stewart JS. Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model. Clin Cancer Res 2000; 6: 4939-4949
21. Koukourakis MI, Koukouraki S, Giatromanolaki A, Archimandritis SC, Skarlatos J, Beroukas K, Bizakis JG, Retalis G, Karkavitsas N, Helidonis ES. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol 1999; 17: 3512-3521
22. Maruyama K, Takizawa T, Yuda T, Kennel SJ, Huang L, Iwatsuru M. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim Biophys Acta 1995; 1234: 74-80
23. Allen TM, Brandeis E, Hansen CB, Kao GY, Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta 1995; 1237: 99-108
24. Bendas G. Immunoliposomes: a promising approach to targeting cancer therapy. BioDrugs 2001; 15: 215-224
25. Berchem GJ, Bosseler M, Mine N, Avalosse B. Nanomolar range docetaxel treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bcl-2. Anticancer Res 1999; 19: 535-540
26. Strunz AM, Peschke P, Waldeck W, Ehemann V, Kissel M, Debus J. Preferential radiosensitization in p53-mutated human tumour cell lines by pentoxifylline-mediated disruption of the G2/M checkpoint control. Int J Radiat Biol 2002; 78: 721-732
27. Yang Y, Yu X. Regulation of apoptosis: the ubiquitous way. FASEB J 2003; 17: 790-799
28. Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC. Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003; 362: 205-209
29. Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, Watanabe N. Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 2000; 91: 1204-1209
30. Rodel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rodel F. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 2003; 55: 1341-1347
31. Lu B, Mu Y, Cao C, Zeng F, Schneider S, Tan J, Price J, Chen J, Freeman M, Hallahan DE. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res 2004; 64: 2840-2845